Company: JUNS
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001261
Chunk: 1538

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 6
Chunk 1538
---
 compensation expense from the effective date of the agreement through the date the obligations are met with the
remaining expense being amortized over the remaining term of the 36-months
per the services agreements. Upon the occurrence of the initial public offering the Company recorded stock based compensation
expense for services provided of $779,411,
and through December 31, 2024 the Company recorded an additional stock based compensation expense of $114,373
for a total stock based compensation expense of $893,784. The future stock based compensation expense as of December 31, 2024 is $3,744,591.

In
addition, each of the entities agreed to purchase 37,500
shares each of the Company’s common stock
at a price of $1.33
per share prior to the occurrence of the IPO
and these shares were registered in the IPO.

Note 9 – Segment Report

The Company’s Chief Executive Officer serves as the
CODM and evaluates the financial performance of the business and makes resource allocation decisions on a consolidated basis. As a result,
the Company operates as a single reportable segment under ASC 280, Segment Reporting, defined by the CODM as JOTROL Drug Development.

The Company operates in one reportable segment, JOTROL Drug Development,
which includes all activities related to the development of JOTROL, to address unmet medical needs and improve the lives of patients.
The determination of a single reportable segment is consistent with the financial information regularly provided to the Company’s
CODM, who reviews and evaluates net loss for purposes of assessing performance, making operating decisions, allocating resources and planning
and forecasting for future periods. The measure of segment assets is reported on the balance sheet as total assets.

Note
10 – Subsequent Events

The
Company evaluated events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the
evaluation and transactions, the Company did not identify any subsequent events that would have required adjustment or disclosure in
the Financial Statements.

F-25

SIGNATURES

Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.

    JUPITER
    NEUROSCIENCES, INC.

    Dated:
    March 28, 2025
    By:
    /s/
    Christer